GILL JOHN

Director John Gill bought 9,200 shares of ALT at $3.41, raising stake 73.6% to 21,700 shares amid cluster buying and -56.8% 52-week decline.

Director John Gill purchased 9,200 shares at $3.41 on 2026-04-06, increasing his holdings by 73.6% from 12,500 to 21,700 shares, while the stock trades at $3.33—down 56.8% from its 52-week high of $7.71. This buy occurs alongside a cluster of 2 other insider purchases within the past 14 days, suggesting coordinated board-level accumulation. However, Gill's prior buy at this ticker (2025-12-23) failed to anticipate a subsequent 90-day decline, and his broader cross-ticker track record shows a 0.00% win rate over 90-day windows despite one prior purchase. The company reported $-19.0M net income and $5.0K quarterly revenue, revealing an unprofitable profile even as full-year revenue grew 105.0%. The insider's significant stake increase during a depressed price environment and amid peer buying warrants tracking whether this reflects accumulation at suppressed valuations or alignment with other governance concerns.

Director John Gill purchases 12,500 shares of ALT at $4.10; stock down 51.5% from 52-week high, company burned $19.0M net in recent period with -95.3% annual revenue decline.

John Gill, a director at Altimmune, initiated a new position with a purchase of 12,500 shares at $4.10 on 2025-12-23, totaling $51,250.00. The purchase occurs in the context of significant headwinds: the stock has fallen 51.5% from its 52-week high of $8.25 and currently trades at $4.00, while fundamentals show the company recorded a net loss of $-19,014,000.00 in its most recent full fiscal year and revenue declined -95.3% year-over-year. This is a small absolute purchase relative to the company's $417,016,692.00 market capitalization, and the director had no prior shareholdings, so this represents entry rather than accumulation. The transaction alone does not provide sufficient signal strength given the shallow position size and the magnitude of underlying operational deterioration.